Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831532 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00831532 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT00831532, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
1. To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic impairment to subjects with normal hepatic function. 2. To assess the safety and tolerability of Dimebon in subjects with hepatic impairment and subjects with normal hepatic function. 3. To explore the pharmacokinetics of Dimebon in subjects with severely-impaired hepatic function.
Interventions
- DRUG Dimebon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831532
The ClinicalTrials.gov registry entry for NCT00831532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dimebon is the first listed.
NCT00831532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831532 about?
NCT00831532 is a clinical study titled "Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function". 1. To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic impairment to subjects with normal hepatic function. 2. To assess the safety and tolerability of Dimebon in subjects with hepatic impairment and subjects with normal hepatic function. 3. To explore the pharmacok...
What is the current status of trial NCT00831532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2009-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00831532?
The interventions under investigation include: Dimebon (DRUG).
Who is sponsoring clinical trial NCT00831532?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.